Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 414 Records) |
Query Trace: Death and EGFR[original query] |
---|
The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study. Cancer medicine 2023 9 . Shuyang Zhang, Lu Yang, Yaning Yang, Guangjian Yang, Haiyan Xu, Xueliang Niu, Yan Wa |
Utility of multigene panel next-generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer. Internal medicine journal 2023 9 . Udit Nindra, Abhijit Pal, Victoria Bray, Po Y Yip, Annette Tognela, Tara L Roberts, Therese M Becker, Jonathon Williamson, Mahtab Farzin, Jing J Li, Vivienne Lea, Abeer Hagelamin, Weng Ng, Bin Wang, C Soon Lee, Wei Ch |
Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data. JCO oncology practice 2023 8 OP2200611. Jeffrey A Scott, Jochen Lennerz, Melissa Lynne Johnson, Lucio N Gordan, Robert H Dumanois, Luca Quagliata, Lauren L Ritterhouse, Federico Cappuzzo, Brandon Wang, Mei Xue, Anupama Vasudevan, Prateesh Varughese, Varun Vaidya, Mike Gart, Natalie Dorrow, Hinco J Gierman, Rushir J Chok |
Association of PD-L1 tumor proportion score ?20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC. Cancer medicine 2023 8 . Yusuke Hamakawa, Yoko Agemi, Aya Shiba, Toshiki Ikeda, Yuko Higashi, Masaharu Aga, Kazuhito Miyazaki, Yuri Taniguchi, Yuki Misumi, Yukiko Nakamura, Tsuneo Shimokawa, Yusuke Saigusa, Nobuaki Kobayashi, Hiroaki Okamoto, Takeshi Kane |
Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study. Frontiers in oncology 2023 8 13 1222716. Daling Dong, Shixin Zhang, Bin Jiang, Wei Wei, Chao Wang, Qian Yang, Tingzhi Yan, Min Chen, Liken Zheng, Weikang Shao, Gang Xio |
First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic. Translational lung cancer research 2023 8 12 (7): 1454-1465. Suganija Lakkunarajah, Pauline T Truong, Jeffrey N Bone, Curtis Hughesman, Stephen Yip, Deepu Alex, Jason Hart, Philip Pollock, Sarah Egli, Melissa Clarkson, Mary Lesperance, Doran Ksiens |
Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer. Thoracic cancer 2023 7 . Si-Yu Lei, Hai-Yan Xu, Hong-Shuai Li, Ya-Ning Yang, Fei Xu, Jun-Ling Li, Zhi-Jie Wang, Pu-Yuan Xing, Xue-Zhi Hao, Yan Wa |
Prognostic implications of the EGFR polymorphism rs763317 and clinical variables among young Chinese lung cancer population. Neoplasma 2023 7 70 (3): 443-450. Zheng-Xing Li, Fan Wang, Zhen-Yu Sun, Chang Xu, Zi-Xiu Zou, Zong-Xu Zhao, Hai-Jian Wang, Shi-Cheng Guo, Li Jin, Qiang Li, Jiu-Cun Wang, Fan Xia, Xiao-Qiang Yue, Junjie |
Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial. Journal of cancer research and clinical oncology 2023 7 . Aidong Qu, Shiying Zhang, Hongxia Zou, Sixiu Li, Dandan Chen, Yaowen Zhang, Songsong Li, Huijun Zhang, Ji Yang, Yunkai Yang, Yubao Huang, Xiuling Li, Yuntao Zha |
Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers. BMC cancer 2023 7 23 (1): 659. Chong Kin Liam, Chian Yih Yew, Yong Kek Pang, Chee Kuan Wong, Mau Ern Poh, Jiunn Liang Tan, Chun Ian Soo, Thian Chee Loh, Ka Kiat Chin, Vijayan Munusamy, Yong Sheng Liam, Nur Husna Ibrah |
A retrospective study of the efficacy of combined EGFR?TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR?TKI monotherapy for PD?L1?positive EGFR?mutant non?small cell lung cancer: North Japan Lung Cancer Study Group 2202. Oncology letters 2023 7 26 (2): 334. Minehiko Inomata, Yosuke Kawashima, Ryota Saito, Daisuke Morinaga, Hitomi Nogawa, Masamichi Sato, Yohei Suzuki, Satoru Yanagisawa, Takashi Kikuchi, Daisuke Jingu, Naruo Yoshimura, Toshiyuki Harada, Eisaku Miyauc |
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 12 JCO2302219. Pasi A Jänne, David Planchard, Kunihiko Kobayashi, Ying Cheng, Chee Khoon Lee, Natalia Valdiviezo, Konstantin Laktionov, Tsung-Ying Yang, Yan Yu, Terufumi Kato, Liyan Jiang, Busyamas Chewaskulyong, Sarayut Lucien Geater, Jean-Marc Maurel, Carlos Rojas, Toshiaki Takahashi, Libor Havel, Frances A Shepherd, Kentaro Tanaka, Dana Ghiorghiu, Neha P Amin, Elena Armenteros-Monterroso, Xiangning Huang, Ammar Ahmed Chaudhry, James Chih-Hsin Ya |
NOS3 and CTH gene mutations as new molecular markers for detection of lung adenocarcinoma. PeerJ 2023 12 11 e16209. Iman Abdullah Ramadhan, Luqman Rahman Sulaiman, Abbas Sali |
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study. Translational lung cancer research 2023 12 12 (11): 2229-2244. Dongming Zhang, Xiaoyan Liu, Fangfang Shen, Dahai Zhao, Yuequan Shi, Haoran Zhang, Jia Liu, Xiaoxing Gao, Minjiang Chen, Jing Zhao, Wei Zhong, Junzhen Gao, Min He, Yonggang Liu, Xiaoling Yang, Jianwen Qin, Yuling Tang, Xinlin Mu, Yangchun Gu, Shucai Zhang, Xueqin Chen, Li Pang, Qingwei Meng, Ye Guo, Yuhui Zhang, Wei Li, Puyuan Xing, Yuan Cheng, Tao Xin, Qingxia Li, Yu Li, Jun Chen, Feng Gao, Bo Jin, Antonio Rossi, Hiroyuki Adachi, Francesco Guerrera, Hatim Husain, Yan Xu, Mengzhao Wa |
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. The New England journal of medicine 2023 11 . David Planchard, Pasi A Jänne, Ying Cheng, James C-H Yang, Noriko Yanagitani, Sang-We Kim, Shunichi Sugawara, Yan Yu, Yun Fan, Sarayut L Geater, Konstantin Laktionov, Chee K Lee, Natalia Valdiviezo, Samreen Ahmed, Jean-Marc Maurel, Igor Andrasina, Jonathan Goldman, Dana Ghiorghiu, Yuri Rukazenkov, Alex Todd, Kunihiko Kobayashi, |
PDL1 and molecular biomarkers expression in non-small cell lung cancer in Tunisian patients. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2023 11 . Yoldez Houcine, Chirine Moussa, Ahmed Ben Abdelaziz, Aida Aya |
Impact of RBM10 and PD-L1 expression on the prognosis of pathologic N1-N2 epidermal growth factor receptor mutant lung adenocarcinoma. Translational lung cancer research 2023 11 12 (10): 2001-2014. Tetsuya Isaka, Yohei Miyagi, Tomoyuki Yokose, Haruhiro Saito, Rika Kasajima, Kozue Watabe, Naoko Shigeta, Noritake Kikunishi, Shunsuke Shigefuku, Kotaro Murakami, Hiroyuki Adachi, Takuya Nagashima, Hiroyuki I |
Prognostic Significance of Pretreatment Plasma D-dimer Levels in EGFR-Positive Advanced Non-Small Cell Lung Cancer Patients Receiving Osimertinib: A Multicentre Retrospective Study. International journal of general medicine 2023 11 16 5481-5491. Qianfei Liu, Liping Tan, Jianbo He, Ruiling Ning, Aiping Zeng, Yilin Ch |
Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study. Journal of thoracic disease 2023 11 15 (10): 5648-5657. Chang Wan, Yiruo Zhang, Pingping Liu, Xinkuan Mei, Gang Cheng, Jingdan Pang, Sheng Chen, Jianping Xu, Jyoti Malhotra, Hesheng Qian, Yingying |
Circulating tumor necrosis factor-related biomarkers predict kidney function decline in Japanese patients with diabetes: An observational cohort study. Diabetes research and clinical practice 2023 11 206 111017. Maki Murakoshi, Nozomu Kamei, Yusuke Suzuki, Mitsunobu Kubota, Michiyoshi Sanuki, Hirotaka Tashiro, Takumi Iwasawa, Kazunori Kato, Marenao Tanaka, Masato Furuhashi, Tomohito Goh |
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. The New England journal of medicine 2023 10 . Marwan G Fakih, Lisa Salvatore, Taito Esaki, Dominik P Modest, David P Lopez-Bravo, Julien Taieb, Michalis V Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietranton |
Analysis of soluble programmed death-1 ligand-1 of lung cancer patients with different characteristics. European review for medical and pharmacological sciences 2023 10 27 (18): 8690-8696. H-B Zhu, X So |
Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy. Journal for immunotherapy of cancer 2023 10 11 (10): . Zichun Li, Xuanye Zhang, Yuhong Wang, Zhixin Yu, Chunlong Yang, Yixin Zhou, Shaodong Ho |
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic advances in medical oncology 2024 1 16 17588359231220606. Jia-Jun Wu, Jeng-Sen Tseng, Zhe-Rong Zheng, Cheng-Hsiang Chu, Kun-Chieh Chen, Mong-Wei Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Sung-Liang Yu, Jin-Shing Chen, Chao-Chi Ho, Gee-Chen Cha |
PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center. Journal of the Egyptian National Cancer Institute 2024 1 36 (1): 3. Sindhu Kilaru, Soumya Surath Panda, Lalatendu Moharana, Debahuti Mohapatra, Satya Sundar G Mohapatra, Adyakinkar Panda, Spoorthy Kolluri, Suma Devaraj, Ghanashyam Bisw |
The detection of PD-L1 expression on liquid-based cytology in pleural effusion of lung adenocarcinoma and its prognostic evaluation: Between paired liquid-based cytology and cell block samples. Diagnostic cytopathology 2024 1 . Haiyue Ma, Jia Jia, Zihan Sun, Xiaoyue Xiao, Shuo Liang, Linlin Zhao, Zhihui Zha |
A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma. Journal of translational medicine 2024 1 22 (1): 87. Jie Peng, Dan Zou, Xudong Zhang, Honglian Ma, Lijie Han, Biao Y |
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer 2024 1 . Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nish |
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC). Translational lung cancer research 2024 1 12 (12): 2448-2459. Dae-Ho Choi, Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Se-Hoon L |
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 2024 1 . Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki I |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 25, 2024
- Content source: